Entos Pharmaceuticals, a clinical-stage genetic medicines company committed to using its Fusogenix PLV technology to develop cures and improve the lives of patients and their families, announced a $62 million investment from the Government of Canada. This investment is in addition totilizes the previously announced $15.5 million awarded to Entos from the Government of Alberta.
The $77.5 million total investment will support a $198.5 million project to create an R&D center and GMP biomanufacturing facility in Edmonton, Alberta, Canada. And the project builds on the significant partnership Entos has with global healthcare leader Eli Lilly & Company to research, develop, and commercialize nucleic acid products targeting the central and peripheral nervous system, and other partnerships with companies such as Oisin Biotechnologies, OncoSenX, and Aegis Life, and to advance its therapeutic pipeline for cancer and rare genetic diseases like Congenital Lipodystrophy, Stargardt Disease and Duchenne Muscular Dystrophy.
As a hub for next-generation therapeutics, this facility aims to foster collaborations between Entos, Canadian academic institutions, and its industry partners. And this effort will build expertise and knowledge to enhance Canada's life sciences sector, strengthen Canada's position in the global biopharmaceutical market, and attract international investments, partnerships, and talent.
Entos is a University of Alberta spin-off company that emerged from the Faculty of Medicine & Dentistry to take research discovery and innovation from the lab and scale up for developing and manufacturing advanced medicines.
KEY QUOTES:
"Our government is protecting the Canadians of tomorrow by making the necessary investments today. By supporting the construction of this state-of-the-art facility in Edmonton, we are strengthening our capacity to produce cutting-edge therapeutics and vaccines, which will better equip Canada in responding to future health emergencies. We are resolved to foster innovation and secure a resilient life sciences ecosystem that will keep Canadians safe for generations to come."
"This new Edmonton facility means that Canada will get a greater capacity to develop lifesaving medicines right here in Canada. It strengthens our domestic biomanufacturing capacity which will lead to improved health outcomes for Canadians."
"Alberta's life sciences sector is booming, and this new manufacturing facility and R&D centre from Entos will only add to the momentum. Alberta is home to many world-class researchers developing potentially ground-breaking new medicines and treatments that will literally save lives. This investment will support Alberta's efforts to become the most innovative jurisdictions in Canada."
"This extraordinary investment from the federal and provincial governments ensures Alberta -- and the University of Alberta -- continues to play a leading role in strengthening Canada's biomanufacturing and pharmaceutical sector. This new research facility will advance research and innovation and improve health outcomes for people in Canada and worldwide."